Lower Risk of Alzheimer’s Disease and Related Dementias associated with Angiotensin Receptor II Blockers (ARBs) treatment for individuals with Hypertension in High‐volume Claims Data

Sori Kim Lundin, Xinyue Hu, Jingna Feng, Karl Kristian Lundin, Lu Li, Yong Chen, Paul E. Schulz, Cui TaoAlzheimer 2024 · DOI

TL;DR

This study suggests that Angiotensin Receptor II Blockers (ARBs), a common class of blood pressure medications, may significantly reduce the risk of developing Alzheimer's disease and related dementias (ADRD) in hypertensive individuals. Notably, ARBs appear more effective than other common antihypertensive drugs, and their ability to cross the blood-brain barrier might play a crucial role in this protective effect.

What Problem Does This Paper Address?

The relationship between antihypertensive medications and the risk of Alzheimer's disease and related dementias (ADRD) has been a subject of ongoing research, with previous findings being inconclusive. Specifically, the protective effects of Angiotensin II Receptor Blockers (ARBs), a widely prescribed class of drugs for hypertension, against ADRD have not been definitively established. This paper aims to clarify this association by investigating whether ARB treatment is linked to a lower incidence of ADRD in a large population of hypertensive patients.

Methods

The researchers employed a retrospective cohort study design using a large, de-identified claims dataset. They identified individuals with hypertension and categorized them based on their antihypertensive medication (AHM) use: ARB users, non-ARB AHM users (including ACE inhibitors and other AHMs), and AHM non-users. To analyze the risk of ADRD, they utilized Kaplan-Meier survival curves to visualize cumulative hazards and adjusted Cox proportional hazards (PH) models to account for potential confounding factors. A novel aspect of their analysis was sub-classifying ARBs based on their blood-brain barrier (BBB) permeability, hypothesizing that BBB-crossing ARBs might have a more pronounced effect.

Datasets

The study utilized the de-identified Clinformatics® Data Mart from Optum, a large claims database containing health records for a substantial population. This dataset included approximately 6.4 million hypertensive individuals. No new benchmarks were introduced; the study leveraged existing claims data to analyze real-world medication use and health outcomes.

Key Insights and Ideas

  • ARBs as a potential neuroprotective agent: The most striking insight is the strong association between ARB use and a reduced risk of ADRD, suggesting these drugs might offer more than just cardiovascular benefits.
  • BBB permeability matters: The finding that ARBs capable of crossing the blood-brain barrier are linked to an even lower ADRD risk is a critical clue. This suggests a direct mechanism of action within the brain, rather than solely indirect effects through blood pressure control.
  • ARBs outperform other antihypertensives: The study indicates that ARBs are not just beneficial, but potentially superior to other common antihypertensive classes like ACE inhibitors in mitigating ADRD risk.

Key Results

  • Reduced ADRD risk with ARBs: ARB users demonstrated a significantly lower adjusted hazard of developing ADRD compared to ACEI users (20% lower), non-ARB/ACEI AHM users (29% lower), and AHM non-users (18% lower).
  • BBB-crossing ARBs show greater benefit: Consumption of BBB-crossing ARBs was associated with an 11% lower risk of ADRD compared to non-BBB-crossing ARBs, a 25% lower risk compared to undetermined ARBs, and a 31% lower risk compared to not using AHMs.
  • Overall lower hazard: Kaplan-Meier curves clearly showed that ARB users had a lower cumulative hazard of ADRD over time compared to other AHM user groups and non-users.
  • Baseline differences: AHM non-users had a lower incidence of comorbidities and lower consumption of metformin and statins compared to ARB users and non-ARB AHM users, indicating potential baseline differences that were accounted for in the adjusted models.

Limitations and Future Work

The authors acknowledge that this is an observational study, and while they adjusted for numerous covariates, residual confounding cannot be entirely ruled out. The findings are based on claims data, which may have limitations in diagnostic accuracy or medication adherence reporting. Future work could involve prospective studies to confirm these findings, investigate the specific mechanisms by which ARBs exert their neuroprotective effects, and explore the optimal ARB subclasses and dosages for ADRD prevention. Further research into the BBB permeability of different ARBs and their direct impact on brain health is also warranted.

Summary updated

Abstract

Abstract Background Findings regarding the protective effect of Angiotensin II receptor blockers (ARBs) against Alzheimer’s disease and related dementias (ADRD) and cognitive decline have been inconclusive. Method A total of 6,390,826 hypertensive individuals were included in this study from Optum’s de‐identified Clinformatics® Data Mart. We identified antihypertensive medication (AHM) drug classes and subclassified ARBs by blood‐brain barrier (BBB) permeability. We compared baseline characteristics and used the Kaplan‐Meier (KM) survival curve and adjusted Cox proportional hazards (PH) model for survival analyses. Result AHM non‐users ( N = 1,184,809) had a lower incidence of all comorbidities and consumption of metformin and statins compared to ARBs users ( N = 1,839,176) and non‐ARBs AHM users ( N = 3,366,841) (all P <0.0001). The KM curve showed that ARB users had lower cumulative hazard than other AHM users or AHM non‐users ( P <0.0001). In Cox PH analysis, ARB users showed a 20% lower adjusted hazard of developing ADRD compared to angiotensin‐converting enzyme inhibitor (ACEI) users and a 29% and 18% reduced risk when compared to non‐ARB/ACEI AHM users and AHM non‐users (all P <0.0001). Consumption of BBB‐crossing ARBs was linked to a lower risk of ADRD development than non‐BBB‐crossing ARBs, undetermined ARBs, and non‐consumption of AHMs by 11%, 25%, and 31% (all P <0.0001). Conclusion This study suggests that ARBs are superior to ACEIs, non‐ARB/ACEI AHMs, or non‐use of AHMs in reducing the risk of ADRD among hypertensive patients. Also, BBB‐permeability in ARBs was associated with lower ADRD risk. There is no cure for AD, ADRD, or vascular dementia; hence, these findings are significant in preventing those disorders in an inexpensive, convenient, and safe way.
BibTeX
@inproceedings{lundin2024lower,
  author = {Sori Kim Lundin and Xinyue Hu and Jingna Feng and Karl Kristian Lundin and Lu Li and Yong Chen and Paul E. Schulz and Cui Tao},
  title = {{Lower Risk of Alzheimer’s Disease and Related Dementias associated with Angiotensin Receptor II Blockers (ARBs) treatment for individuals with Hypertension in High‐volume Claims Data}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.084745},
}
Figure